Terms: = Kidney tumors AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546
63 results:
1. Circulating inflammatory cytokines in relation to the risk of renal cell carcinoma: A gender-specific two-sample Mendelian randomization study.
Tao S; Lin Y; Huang S; Lin S; Jin K; Chen H
Cancer Med; 2023 Nov; 12(22):21013-21021. PubMed ID: 37902279
[TBL] [Abstract] [Full Text] [Related]
2. Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma.
Lu Y; Zhu Y; Ma W; Liu N; Dong X; Shi Q; Yu F; Guo H; Li D; Gan W
Sci Rep; 2023 Apr; 13(1):6141. PubMed ID: 37061606
[TBL] [Abstract] [Full Text] [Related]
3. Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure.
Huang SC; Chang IY; Chang CJ; Liu H; Chen KH; Liu TT; Hsieh TY; Chuang HC; Chen CC; Lin IC; Ng KF; Huang HY; Chen TC
J Pathol; 2023 Jun; 260(2):165-176. PubMed ID: 36815532
[TBL] [Abstract] [Full Text] [Related]
4. Gene fusions are frequent in ACTH-secreting neuroendocrine neoplasms of the pancreas, but not in their non-pancreatic counterparts.
Agaimy A; Kasajima A; Stoehr R; Haller F; Schubart C; Tögel L; Pfarr N; von Werder A; Pavel ME; Sessa F; Uccella S; La Rosa S; Klöppel G
Virchows Arch; 2023 Mar; 482(3):507-516. PubMed ID: 36690805
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Characterization of Malignant Renal Epithelioid Angiomyolipoma: A Review of Two Cases.
Rammal R; Korentzelos D; Skaugen JM; Quiroga-Garza GM
Am J Clin Pathol; 2023 Mar; 159(3):211-220. PubMed ID: 36661215
[TBL] [Abstract] [Full Text] [Related]
6. Molecular subtypes based on metabolic genes are potential biomarkers for predicting prognosis and immune responses of clear cell renal cell carcinoma.
Wang Y; Ji H; Zhu B; Xing Q; Xie H
Eur J Immunol; 2023 Jan; 53(1):e2250105. PubMed ID: 36367018
[TBL] [Abstract] [Full Text] [Related]
7. Molecular and Immunophenotypic Correlates of Metastatic Epithelioid Angiomyolipoma Include Alterations of TP53, RB1, and atrx.
McCarthy MR; Nichols PE; Sharma V; Stanton ML; Reynolds JP; Pitel BA; Halling KC; Lohse CM; Herrera-Hernandez L; Thompson RH; Leibovich BC; Jimenez RE; Boorjian SA; Cheville JC; Gupta S
Arch Pathol Lab Med; 2023 Jul; 147(7):817-825. PubMed ID: 36308711
[TBL] [Abstract] [Full Text] [Related]
8. Impairment of kidney function and kidney cancer: A bidirectional Mendelian randomization study.
Lin Y; Yang Y; Fu T; Lin L; Zhang X; Guo Q; Chen Z; Liao B; Huang J
Cancer Med; 2023 Feb; 12(3):3610-3622. PubMed ID: 36069056
[TBL] [Abstract] [Full Text] [Related]
9. Association between secondhand smoke and cancers in adults in the US population.
Zhang Z; Li Z; Zhang X; Ye W; Chen J; Wang L; Lin Z; Li J; Li Z
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3447-3455. PubMed ID: 35943599
[TBL] [Abstract] [Full Text] [Related]
10.
Baek J; Jang NR; Shim YR; Gu MJ
Indian J Pathol Microbiol; 2022; 65(3):598-603. PubMed ID: 35900487
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Uemura H; Albiges L; Fujii Y; Umeyama Y; Wang J; Mariani M; Schmidinger M
ESMO Open; 2022 Apr; 7(2):100450. PubMed ID: 35397432
[TBL] [Abstract] [Full Text] [Related]
12. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
[TBL] [Abstract] [Full Text] [Related]
13. Brain Metastases among Cancer Patients Diagnosed from 2010-2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence.
Liu JL; Walker EV; Paudel YR; Davis FG; Yuan Y
Curr Oncol; 2022 Mar; 29(3):2091-2105. PubMed ID: 35323369
[TBL] [Abstract] [Full Text] [Related]
14. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Regan MM; Jegede OA; Mantia CM; Powles T; Werner L; Motzer RJ; Tannir NM; Lee CH; Tomita Y; Voss MH; Plimack ER; Choueiri TK; Rini BI; Hammers HJ; Escudier B; Albiges L; Huo S; Del Tejo V; Stwalley B; Atkins MB; McDermott DF
Clin Cancer Res; 2021 Dec; 27(24):6687-6695. PubMed ID: 34759043
[TBL] [Abstract] [Full Text] [Related]
15. Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat.
Mitsuboshi S; Niimura T; Kanda M; Ishida S; Zamami Y; Ishizawa K
Ann Pharmacother; 2022 Aug; 56(8):910-915. PubMed ID: 34726078
[TBL] [Abstract] [Full Text] [Related]
16. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia.
Welliver C; Feinstein L; Ward JB; Kirkali Z; Martinez-Miller EE; Matlaga BR; McVary K
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):269-273. PubMed ID: 34545201
[TBL] [Abstract] [Full Text] [Related]
17. Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients.
Gupta S; Jimenez RE; Herrera-Hernandez L; Lohse CM; Thompson RH; Boorjian SA; Leibovich BC; Cheville JC
Mayo Clin Proc; 2021 Jun; 96(6):1470-1489. PubMed ID: 33526281
[TBL] [Abstract] [Full Text] [Related]
18. Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.
Uhlig A; Uhlig J; Trojan L; Woike M; Leitsmann M; Strauß A
Future Oncol; 2021 Jan; 17(1):45-56. PubMed ID: 33275038
[TBL] [Abstract] [Full Text] [Related]
19. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
[TBL] [Abstract] [Full Text] [Related]
20. Outcomes of arteriovenous access among cancer patients requiring chronic haemodialysis.
Jeong S; Kwon H; Chang JW; Han Y; Kwon TW; Cho YP
BMC Nephrol; 2020 Jul; 21(1):297. PubMed ID: 32703168
[TBL] [Abstract] [Full Text] [Related]
[Next]
